IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Discovery themes featuring this stock
Upcoming Result Date: Nov 13, 2026
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
3
Neutral
7
Bullish
4
Bearish
29
Neutral
9
Bullish
8
Bearish
26
Neutral
2
Bullish
4
Bearish
26
Neutral
2
Bullish
4
Bearish
26
Neutral
2
Bullish
4
Bearish
26
Neutral
2
Bullish
4
Decipher Labs Ltd (DECIPHER) is currently trading at 5.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Decipher Labs Limited is a diversified public company operating two clear segments: manufacturing and trading of pharmaceutical formulations, and information technology consultancy and services, supported by overseas subsidiaries Decipher Software Solutions LLC (USA) and Decipher Soft Middle East W.L.L (Bahrain). The group combines legacy pharma manufacturing with an expanded IT services footprint through acquisitions and exports. Recent consolidated quarterly results show total revenue of INR 251.13 lakhs with operating expenses of INR 469.66 lakhs, producing a consolidated loss before tax of INR 218.52 lakhs and a net loss of INR 218.57 lakhs attributable to owners; this highlights near-term profitability pressure and a wide operating loss driven largely by the consultancy/IT cost base in the quarter. Segment profile is heavily weighted to consultancy and IT services this quarter, with consultancy revenue at INR 240.99 lakhs versus manufacturing at INR 0.40 lakhs on consolidated basis, indicating that Decipher Labs Limited’s recent growth and volatility are driven by the IT subsidiary performance and integration rather than domestic pharmaceutical sales. Governance and reporting show board oversight and audit review procedures: the board approved revised unaudited standalone results on 13 August 2026 to correct a typographical error, and independent auditors issued a review report with no modifications, reflecting formal compliance though the company is navigating negative profitability and auditing reliance on other auditors for subsidiary results. The company is evaluating regulatory changes driven by India’s New Labour Codes effective November 2025, and has estimated no immediate liability for direct employees while still assessing impacts for contract workforce; this regulatory assessment is material given the company’s significant consultancy services and overseas staffing through subsidiaries.
Over the past 52 weeks, Decipher Labs Ltd has traded between a low of ₹4.81 and a high of ₹10.99. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Decipher Labs Ltd has a market capitalization of approximately 5.56. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Decipher Labs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -1.81 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 5.56 Cr, Decipher Labs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Decipher Labs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Decipher Labs Ltd is -1.81. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
12.50 | 7 Cr | 73.90 | 0.89 | 0.00 | 1.14 | 2.54 | 1.02 | ||
22.00 | 7 Cr | 8.15 | 1.46 | 0.00 | 18.05 | -2.59 | 4.23 | ||
1.47 | 6 Cr | 147.00 | 1.27 | 0.00 | 0.60 | 3.76 | 0.14 | ||
5.50 | 6 Cr | -1.81 | 0.27 | 0.00 | -14.93 | -17.41 | -12.62 | ||
20.31 | 4 Cr | -7.62 | 1.17 | 0.00 | -15.32 | -11.50 | -2.53 | ||
3.50 | 4 Cr | 39.11 | 0.34 | 0.00 | 1.11 | 1.49 | 1.16 | ||
— | 0 Cr | 0.05 | 0.02 | 0.00 | -0.61 | -0.18 | 38.20 | ||
| Median: 7 Co. | — | 9.00 | 6 Cr | 8.15 | 0.89 | 0.00 | 0.60 | -0.18 | 1.02 |
Decipher Labs Limited is a diversified public company operating two clear segments: manufacturing and trading of pharmaceutical formulations, and information technology consultancy and services, supported by overseas subsidiaries Decipher Software Solutions LLC (USA) and Decipher Soft Middle East W.L.L (Bahrain). The group combines legacy pharma manufacturing with an expanded IT services footprint through acquisitions and exports.
Recent consolidated quarterly results show total revenue of INR 251.13 lakhs with operating expenses of INR 469.66 lakhs, producing a consolidated loss before tax of INR 218.52 lakhs and a net loss of INR 218.57 lakhs attributable to owners; this highlights near-term profitability pressure and a wide operating loss driven largely by the consultancy/IT cost base in the quarter.
Segment profile is heavily weighted to consultancy and IT services this quarter, with consultancy revenue at INR 240.99 lakhs versus manufacturing at INR 0.40 lakhs on consolidated basis, indicating that Decipher Labs Limited’s recent growth and volatility are driven by the IT subsidiary performance and integration rather than domestic pharmaceutical sales.
Governance and reporting show board oversight and audit review procedures: the board approved revised unaudited standalone results on 13 August 2026 to correct a typographical error, and independent auditors issued a review report with no modifications, reflecting formal compliance though the company is navigating negative profitability and auditing reliance on other auditors for subsidiary results.
The company is evaluating regulatory changes driven by India’s New Labour Codes effective November 2025, and has estimated no immediate liability for direct employees while still assessing impacts for contract workforce; this regulatory assessment is material given the company’s significant consultancy services and overseas staffing through subsidiaries.
Pharmaceuticals & Biotechnology
Pharmaceuticals
6 Cr
Moderate Risk
-1.8
39.5
—
0.3
10.99
4.81
Sales CAGR
Profit CAGR
ROE
ROCE
